bioMerieux SA · EURONEXT:BIM
bioMerieux SA — H1 2020 Earnings Presentation
30 slides from bioMerieux SA's earnings presentation, Sep 2, 2020
Slide 1: HY 2020 Results & 2020 Outlook
HY 2020 Results & 2020 Outlook Investor Presentation – September 2nd, 2020 PIONEERING DIAGNOSTICS
Slide 2: Disclaimer
Disclaimer This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieu
Slide 3: Agenda
AGENDA OVERVIEW OF BIOMERIEUX HY 2020 ACTIVITY REVIEW HY 2020 FINANCIAL RESULTS 2020 OUTLOOK
Slide 4: bioMérieux at a glance – 2019 figures
bioMérieux at a glance – 2019 figures + 55 YEARS CLINICAL APPLICATIONS OF EXPERTISE IN INDUSTRIAL APPLICATIONS 82% of revenues IN VITRO DIAGNOSTICS 18% of revenues Sales amounting to 92% €2.7 billion of international sales About Strong commitment 1,800 people 12,000 to innovation14% dedicated to R&D
Slide 5: bioMérieux: mission, strategy and strengths
bioMérieux: mission, strategy and strengths PIONEERING DIAGNOSTICS To improve public health, focused on the fight against infectious diseases MICROBIOLOGY MOLECULAR IMMUNOASSAYS Two leadership positions BIOLOGY Specialized in both clinical and industrial Leader in the syndromic diagnosis high medica
Slide 6: bioMérieux provides solutions to manage infectious diseases and improve patient care
bioMérieux provides solutions to manage infectious diseases and improve patient care Antimicrobial Protecting resistance consumers' health Respiratory Sepsis & infections emergency care 6
Slide 7: Agenda
AGENDA OVERVIEW OF BIOMERIEUX HY 2020 ACTIVITY REVIEW HY 2020 FINANCIAL RESULTS 2020 OUTLOOK
Slide 8: Key take-away messages
KEY TAKE-AWAY MESSAGES strong H1, driven by unprecedented demand for molecular GLOBAL HEALTH CONTRASTED TRENDS Comprehensive range of in vitro diagnostic solutions to address the Molecular biology different needs of COVID-19 patients Industry Microbiology Immunoassays SALES PROFITABILITY FREE CASH F
Slide 9: Comprehensive in vitro diagnostic solutions for COVID-19
COMPREHENSIVE IN VITRO DIAGNOSTIC SOLUTIONS FOR COVID-19 EXTRACTION PCR TEST SYNDROMIC SEROLOGY EMAG® & EASYMAG® ARGENE® SARS-CoV-2 R-GENE® BIOFIRE® RP2.1 VIDAS® anti-SARS-CoV-2 IgM BIOFIRE® RP2.1plus VIDAS® anti-SARS-CoV-2 IgG high quality and fully automated Ready-to-use kits with internal Rapid,
Slide 10: Acting responsibly to the COVID-19 situation
ACTING RESPONSIBLY TO THE COVID-19 SITUATION Protecting the health, safety and well-being of our employees Implementation of specific measures to ensure safety (home office, hygiene and equipment protection, …) Financial and logistic support (exceptional bonus, childcare, …) Well-being and psy
Slide 11: BIOFIRE driven by unprecedented demand
MOLECULAR BIOLOGY BIOFIRE® driven by unprecedented demand Installed base from 10,400 to 14,000 units +20% Sales outside USA of about 20% +37% +64% BIOFIRE® FILMARRAY ® sales +50% Future growth drivers +60% 605 489 483 Grow the installed base and its consumption 368 +80% Enlarge the BIOFIRE® FILM
Slide 12: Expanding BIOFIRE manufacturing capacities with the 1001 Building
EXPANDING BIOFIRE MANUFACTURING CAPACITIES WITH THE OPENING OF THE « 1001 BUILDING » HEADQUARTERS 1001 MANUFACTURING BUILDING Global functions Gradual expansion of production capacities for reagents & R&D instruments Manufacturing of reagents & instruments Phased automation of the manufact
Slide 13: Trends on other key ranges
TRENDS ON OTHER KEY RANGES CLINICAL APPLICATIONS INDUSTRIAL APPLICATIONS COVID-19 Overall reduced hospital traffic Closure of restaurants, catering services Social distancing lowering infectious Reduced production volumes impacts diseases transmissions Reduced access to customer sites Impa
Slide 14: Agenda
AGENDA OVERVIEW OF BIOMERIEUX HY 2020 ACTIVITY REVIEW HY 2020 FINANCIAL RESULTS 2020 OUTLOOK
Slide 15: HY 2020 sales
HY 2020 sales Currency Change in scope of Organic effect consolidation growth + € 200m + € 2m USD (1) + €17m +15.7% €1,476m LatAm (2) - €12m Asia (3) - €2m €1,275m Metera (4) - €3m + 15.8% HY 2019 HY 2020 15 (1) Including HKD (2) ARS, BRL, CLP, COP, MXN (3) AUD, CNY, INR, JPY, KRW, SGD, THB (4) TRY,
Slide 16: HY 2020 sales by application
HY 2020 sales by application: contrasted performance due to COVID-19 impacts €45m 3% INDUSTRY +1% €219m MICROBIOLOGY -4% 15% €460m 31% GROUP Clinical applications (85%) €1,476m +19% +15.7% €557m €195m MOLECULAR +69% 38% 13% IMMUNOASSAYS -14% 16
Slide 17: HY 2020 sales by geography
HY 2020 sales by geography: strong momentum in AMERICAS driven by molecular AMERICAS ASPAC €762m €241m 52% of sales 16% of sales +30% +2% EMEA €473m 32% of sales HY 2020 REVENUES €1,476m +4% ORGANIC GROWTH +15.7% 17
Slide 18: HY 2020 consolidated P&L
HY 2020 consolidated P&L: sales dynamics & OPEX savings driving profitability In €m HY As a % HY As a % % change % change of sales of sales as reported at constant 2020 2019 exchange rates and scope Net sales 1,476 100% 1,275 100% + 15.8% + 15.7% Cost of sales -660 -44.7% -565 -44.3% + 16,8% + 15.4%
Slide 19: HY 2020 contributive operating margin
HY 2020 contributive operating margin: strong leverage partially offset by phantom share plans +32% - € 14m - € 16m - € 7m - € 1m + € 93m € 261m € 253m 17.7% 17.1% € 198m 15.5% HY 2019 Operational US pension Phantom HY 2020 at FX Scope HY 2020 improvement settlement share plan CER & scope var. var.
Slide 20: HY 2020 consolidated P&L: from contributive operating income to EPS
HY 2020 consolidated P&L: from contributive operating income to EPS In €m HY As a % HY As a % % change of sales of sales as reported 2020 2019 Contributive operating income 253 17.1% 198 15.0% + 27.8% BioFire acquisition related costs - 9 - 9 Other non-recurring expenses - 12 Operating income 232 15
Slide 21: HY 2020 tax rate
HY 2020 tax rate French tax rate 32.0% Foreign & reduced tax rates -6.7% -6.7% Mainly due to US tax rate Tax credits -2.0% -2.0% Mainly R&D Tax Credit FDII (1) -1.3% -1.3% Implemented in 2019 Others (2) 0.3% 0.3% Recurring effective tax rate 22.3% Non-recurring items -0.6% -0.6% Sponsorship
Slide 22: HY 2020 cash flow statement
HY 2020 cash flow statement 9% of sales Manufacturing capacity increase at BIOFIRE® Leverage -€22m 0.3x EBITDA -€68m NEW FINANCING -€127m €200m EuroPP bond, +€345m 1.61%, 7-10y maturity +€18m -€9m -€10m Free Cash Flow (1) €-317m €-192m €144m Net debt as EBITDA WCR Income tax & CAPEX Other cash Acq
Slide 23: Agenda
AGENDA OVERVIEW OF BIOMERIEUX HY 2020 ACTIVITY REVIEW HY 2020 FINANCIAL RESULTS 2020 OUTLOOK
Slide 24: 2020 Outlook
2020 OUTLOOK In light of the uncertainties linked to the current health crisis, bioMérieux has deemed it preferable not to issue any new annual guidance as of the date of release of its interim results. Nevertheless, based on the robust first-half performance and the nature of bioMérieux’s business,
Slide 25: Pioneering Diagnostics
PIONEERING DIAGNOSTICS
Slide 26: Our microbiology offer
OUR MICROBIOLOGY OFFER TESTING ANTIBIOTIC SUSCEPTIBILITY CULTURE IDENTIFICATION APPLICATIONS CLINICAL CHROMID® Culture Media VITEK® MS PREVI® RAPIDEC® ETEST® (MALDI-TOF) COLOR GRAM CARBA NP APPLICATIONS INDUSTRIAL WASP® WASPLab® API® strips VITEK® ID cards VITEK® AST cards BACT/ALERT VIRTUO ® BACT/A
Slide 27: Our immunoassay & molecular biology offer
OUR IMMUNOASSAY & MOLECULAR BIOLOGY OFFER MOLECULAR BIOLOGY IMMUNOASSAYS APPLICATIONS CLINICAL VIDAS® 3 VIDAS® MINI VIDAS® BIOFIRE® BIOFIRE® FILMARRAY® TORCH FILMARRAY® 2.0 SYNDROMIC TESTING VIDAS® reagents APPLICATIONS INDUSTRIAL EMAG® ESTREAM® HYBIOME® AE-240 ARGENE® 27 To know more about the whol
Slide 28: Our industrial offer
OUR INDUSTRIAL OFFER HEALTHCARE AGRI-FOOD APPLICATIONS CLINICAL BLUE LINE™ MASTERCLAVE® VERIFLOW® 3P® BIOBALL® GENE-UP® VIDAS® TEMPO® BACT/ALERT® SCANRDI® BACT/ALERT® APPLICATIONS VIRTUO® INDUSTRIAL Chromogenic Media VITEK® MS VITEK® 2 API® LABGUARD® 28 To know more about the whole bioMérieux offer
Slide 29: bioMérieux is recognized for its Corporate Social Responsibility policy
bioMérieux is recognized for its Corporate Social Responsibility policy RESPONSIBILITY RESPONSIBILITY RESPONSIBILITY TO THE TO OUR WORKFORCE TO THE SOCIETY ENVIRONNEMENT Create an optimal working Help make diagnostics accessible, Reduce and control our environment through a commitment to address env
Slide 30: Contacts
CONTACTS Ordinary shares (EUR) Sylvain MORGEAU / Franck ADMANT ISIN: FR0013280286 Investor Relations bioMérieux is listed on Euronext Paris [email protected] Reuters: BIOX.PA / Bloomberg: BIM.FP [email protected] American Depository Receipt (1:0.1 USD) Reuters: BMXXY.PK / Blo